Arterial-Portal Venous Shunt after Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma Patients: Risk factors and Impact on Patient Survival
Oncology · 2024
DOI: 10.1159/000537867 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Phan Nhan Hien und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, hienpn0600@hmuh.…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Portal Vein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC) has been well established. The differential impacts of drug-eluting bead TACE (DEB-TACE) as opposed to conventional TACE (cTACE) on vascular changes, such as arterial-portal venous shunts (APSs), have been recognized. However, their subsequent effects on treatment outcomes have not been fully explored. This study aims to identify risk factors associated with the occurrence of APS in HCC patients treated with DEB-TACE and to evaluate its impact on patient survival.
Methods
A retrospective analysis was conducted from January 2012 to December 2018 including 74 HCC patients receiving DEB-TACE as initial treatment and a 1:1 cTACE. Kaplan-Meier analysis estimated overall survival (OS) and progression-free survival (PFS). Logistic regression identified significant risk factors for APS occurrence after DEB-TACE.
Results
APS incidence was significantly higher after DEB-TACE than cTACE (46.0% vs. 16.2%, p < 0.001). There was no significant difference in median OS between APS and non-APS groups after DEB-TACE: 50 months (24.6–75.4) versus 26.9 months (19.5–43.2), p = 0.111; median PFS was 15.6 months (4.1–27.1) and 9.5 months (6.8–12.1) for the two groups, respectively, p = 0.065. Risk factors for APS occurrence after DEB-TACE were more than two feeding arteries (OR: 7.25, 95% CI: 1.82–28.95, p = 0.005) and non-selective embolization (OR: 8.02, 95% CI: 2.30–27.95, p = 0.001).
Conclusion
APS occurrence was higher in DEB-TACE-treated HCC patients, but it did not significantly affect OS and PFS. More than two feeding arteries and non-selective embolization were significant risk factors for APS occurrence after DEB-TACE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, hienpn0600@hmuh.vn.
- Radiology Centre, Hanoi Medical University Hospital, Hanoi, Vietnam, hienpn0600@hmuh.vn.
- Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Zitieren
APA
Hien, P. N., Chun, H. J., Oh, J. S., Kim, S. H., & Choi, B. G. (2024). Arterial-Portal Venous Shunt after Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma Patients: Risk factors and Impact on Patient Survival. Oncology. https://doi.org/10.1159/000537867
Vancouver
Hien PN, Chun HJ, Oh JS, Kim SH, Choi BG. Arterial-Portal Venous Shunt after Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma Patients: Risk factors and Impact on Patient Survival. Oncology. 2024. doi:10.1159/000537867
BibTeX
@article{Hien2024,
author = {Hien, Phan Nhan and Chun, Ho Jong and Oh, Jung Suk and Kim, Su Ho and Choi, Byung Gil},
title = {Arterial-Portal Venous Shunt after Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma Patients: Risk factors and Impact on Patient Survival},
journal = {Oncology},
year = {2024},
doi = {10.1159/000537867}
}
EUVIMED